A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

This ia a Phase I, randomized, placebo-controlled, double-blind study in three groups of healthy adult males or sterile females who are BCG-vaccinated, HIV-negative, and have no evidence of tuberculosis infection.

Sixty-four subjects assigned to one of eight treatment groups to receive one of four different antigen/adjuvant combinations of study vaccine, or placebo control. Within each study group, subjects will be randomized to receive either a single-dose antigen/adjuvant regimen of study vaccine (vaccination with study vaccine on Study Day 0 followed by vaccination with placebo control on Study Day 56) or a two-dose antigen/adjuvant regimen of study vaccine (vaccination with study vaccine on Study Days 0 and 56).

All subjects will be followed for safety and immunogenicity evaluations for 182 days.

The sample sizes specified for each study group were selected because they are judged to be adequate for preliminary safety and immunogenicity evaluations for a Phase I study rather than for statistical reasons. If no SAE are observed among 56 subjects receiving active study vaccine, an approximation to the upper 95% confidence bound on the rate of SAE occurrence would be 5.4%.

Inclusion criteria

• Male or female
• Age 18 through 50 years on Study Day 0
• Completed wriiten Informed Consent
• BCG vaccination at least 5 years ago,
• General good health, confirmed by medical history
• (BMI) between 19 and 33 (kg/m2)
• Has ability to complete follow-up period of 182 days as required
• Females must be physically incapable of conception
• Avoiding elective surgery for the duration of the study
• Stay in contact with the investigative site for the duration of the study
• Complete simultaneous enrollment in Aeras Vaccine Development Registry protocol

Exclusion criteria

• Acute illness on the day of randomization
• Oral temperature >=37.5 degree Celcius on the day of randomization
• Evidence of significant active infection
• Used immunosuppressive medication within 42 days before entry into the study
• Received immunoglobulin or blood products within 42 days before entry into the study
• Received any investigational drug therapy or investigational vaccine within 182 days
• Received inactivated influenza vaccine or inactivated tick-borne encephalitis vaccine within 14 days before entry into the study.
• Current chronic drug therapy including hormone replacement such as thyroxin, insulin, etc.
• History or laboratory evidence of any past, present or future possible immunodeficiency state which will include any laboratory indication of virus type 1 (HIV-1) infection
• History of allergic disease or reactions, including eczema.
• Previous medical history that may compromise safety of subject
• Evidence of new acute illness that may compromise safety of subject
• Evidence of chronic hepatitis
• Inability to discontinue daily medication except contraception
• History of alcohol or drug abuse within 2yrs
• Tobacco or cannabis smoking three
• Positive urine test for illicit drugs
• History or evidence of any systemic disease on physical examination
• History of active TB
• Shared residence within 1 year with an individual on anti-TB treatment
• All females: nursing
• Abnormal hemoglobin,hematocrit etc drawn within 36 hours prior to randomization
• Laboratory test evidence of Mtb infection
• History of positive tuberculin skin test within past 10 years
• Received a tuberculin skin test within 3 years
• History of autoimmune disease